Effect of pravastatin treatment on circulating adiponectin: a meta-analysis of randomized controlled trials

References

• PetersBMaitland-van der ZeeAHPharmacogenomic importance of pravastatinPharmacogenomics2008991207121018781848
   PubMed Web of Science ®Google Scholar
• GottoAMReview of primary and secondary prevention trials with lovastatin, pravastatin, and simvastatinAm J Cardiol2005965A3438
   PubMed Web of Science ®Google Scholar
• del SolAINanayakkaraPWPravastatin: an evidence-based statin?Expert Opin Drug Metab Toxicol20084682182518611121
   PubMed Web of Science ®Google Scholar
• McGovernMEMelliesMJLong-term experience with pravastatin in clinical research trialsClin Ther199315157648458055
   PubMed Web of Science ®Google Scholar
• ByingtonRPSacksFMLessons learned from the prospective pravastatin Pooling ProjectCurr Atheroscler Rep20046536637415296703
   PubMedGoogle Scholar
• AdhyaruBBJacobsonTASafety and efficacy of statin therapyNat Rev Cardiol2018151275776930375494
   PubMed Web of Science ®Google Scholar
• CarterAAGomesTCamachoXJuurlinkDNShahBRMamdaniMMRisk of incident diabetes among patients treated with statins: population based studyBMJ2013346f261023704171
   PubMed Web of Science ®Google Scholar
• ZaharanNLWilliamsDBennettKStatins and risk of treated incident diabetes in a primary care populationBr J Clin Pharmacol20137541118112422845189
   PubMed Web of Science ®Google Scholar
• DanaeiGGarcía RodríguezLAFernandez CanteroOHernánMAStatins and risk of diabetes: an analysis of electronic medical records to evaluate possible bias due to differential survivalDiabetes Care20133651236124023248196
   PubMed Web of Science ®Google Scholar
• AgarwalaAKulkarniSMaddoxTThe association of statin therapy with incident diabetes: evidence, mechanisms, and recommendationsCurr Cardiol Rep20182075029779165
   PubMed Web of Science ®Google Scholar
• Esteve-ValverdeEFerrer-OliverasRGil-AliberasNBaraldès-FarréALlurbaEAlijotas-ReigJPravastatin for preventing and treating preeclampsia: a systematic reviewObstet Gynecol Surv2018731405529368790
   PubMed Web of Science ®Google Scholar
• LeeSKwakHBRole of adiponectin in metabolic and cardiovascular diseaseJ Exerc Rehabil2014102545924877038
   PubMedGoogle Scholar
• Ebrahimi-MamaeghaniMMohammadiSArefhosseiniSRFallahPBaziZAdiponectin as a potential biomarker of vascular diseaseVasc Health Risk Manag201511557025653535
   PubMedGoogle Scholar
• RuanHDongLQAdiponectin signaling and function in insulin target tissuesJ Mol Cell Biol20168210110926993044
   PubMed Web of Science ®Google Scholar
• KanhaiDAKranendonkMEUiterwaalCSvan der GraafYKappelleLJVisserenFLAdiponectin and incident coronary heart disease and stroke. A systematic review and meta-analysis of prospective studiesObes Rev201314755556723495931
   PubMed Web of Science ®Google Scholar
• LiSShinHJDingELvan DamRMAdiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysisJAMA2009302217918819584347
   PubMed Web of Science ®Google Scholar
• SaitoSFujiwaraTMatsunagaTIncreased adiponectin synthesis in the visceral adipose tissue in men with coronary artery disease treated with pravastatin: a role of the attenuation of oxidative stressAtherosclerosis2008199237838318164019
   PubMed Web of Science ®Google Scholar
• Gannagé-YaredMHAzarRRAmm-AzarMPravastatin does not affect insulin sensitivity and adipocytokines levels in healthy non-diabetic patientsMetabolism200554794795115988706
   PubMed Web of Science ®Google Scholar
• TrøseidMLappegårdKTMollnesTEArnesenHSeljeflotIChanges in serum levels of E-selectin correlate to improved glycaemic control and reduced obesity in subjects with the metabolic syndromeScand J Clin Lab Invest200565428329016076683
   PubMed Web of Science ®Google Scholar
• SugiyamaSFukushimaHKugiyamaKPravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery diseaseAtherosclerosis20071942e43e5117112529
   PubMed Web of Science ®Google Scholar
• TakagiTMatsudaMAbeMEffect of pravastatin on the development of diabetes and adiponectin productionAtherosclerosis2008196111412117391675
   PubMed Web of Science ®Google Scholar
• KohKKQuonMJHanSHDifferential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patientsAtherosclerosis2009204248349018977478
   PubMed Web of Science ®Google Scholar
• KimJHLeeMRShinJAEffects of pravastatin on serum adiponectin levels in female patients with type 2 diabetes mellitusAtherosclerosis2013227235535923466100
   PubMed Web of Science ®Google Scholar
• KohKKLimSChoiHCombination pravastatin and valsartan treatment has additive beneficial effects to simultaneously improve both metabolic and cardiovascular phenotypes beyond that of mono-therapy with either drug in patients with primary hypercholesterolemiaDiabetes201362103547355223863812
   PubMed Web of Science ®Google Scholar
• KohKKQuonMJSakumaIDifferential metabolic effects of rosuvastatin and pravastatin in hypercholesterolemic patientsInt J Cardiol2013166250951522204857
   PubMed Web of Science ®Google Scholar
• ChruścielPSahebkarARembek-WieliczkoMImpact of statin therapy on plasma adiponectin concentrations: a systematic review and meta-analysis of 43 randomized controlled trial armsAtherosclerosis201625319420827498397
   PubMed Web of Science ®Google Scholar
• YokoyamaHSaitoSDaitokuKEffects of pravastatin and rosuvastatin on the generation of adiponectin in the visceral adipose tissue in patients with coronary artery diseaseFundam Clin Pharmacol201125337838720608995
   PubMed Web of Science ®Google Scholar
• FichtenbaumCJYehTMEvansSRAbergJATreatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087J Clin Lipidol20104427928720824151
   PubMed Web of Science ®Google Scholar
• MoherDLiberatiATetzlaffJAltmanDGPRISMA GroupPreferred reporting items for systematic reviews and meta-analyses: the PRISMA statementBMJ2009339b253519622551
   PubMed Web of Science ®Google Scholar
• HigginsJGreenSCochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration2011 Available from: https://training.cochrane.org/handbookAccessed on January 15, 2019
   Google Scholar
• HigginsJPThompsonSGDeeksJJAltmanDGMeasuring inconsistency in meta-analysesBMJ2003327741455756012958120
   PubMed Web of Science ®Google Scholar
• EggerMDavey SmithGSchneiderMMinderCBias in meta-analysis detected by a simple, graphical testBMJ199731571096296349310563
   PubMed Web of Science ®Google Scholar
• WoodwardLAkoumianakisIAntoniadesCUnravelling the adiponectin paradox: novel roles of adiponectin in the regulation of cardiovascular diseaseBr J Pharmacol2017174224007402027629236
   PubMed Web of Science ®Google Scholar
• ArnaboldiLCorsiniACould changes in adiponectin drive the effect of statins on the risk of new-onset diabetes? The case of pitavastatinAtheroscler Suppl20151612725575403
   PubMed Web of Science ®Google Scholar
• ChenYOhmoriKMizukawaMDifferential impact of atorvastatin vs pravastatin on progressive insulin resistance and left ventricular diastolic dysfunction in a rat model of type II diabetesCirc J200771114415217186993
   PubMed Web of Science ®Google Scholar
• ArakiKMasakiTKatsuragiIKakumaTYoshimatsuHEffects of pravastatin on obesity, diabetes, and adiponectin in diet-induced obese miceObesity20081692068207319186331
   PubMed Web of Science ®Google Scholar
• NiemiMPasanenMKNeuvonenPJSLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatinClin Pharmacol Ther200680435636617015053
   PubMed Web of Science ®Google Scholar
• DangasGSmithDABadimonJJGender differences in blood thrombogenicity in hyperlipidemic patients and response to pravastatinAm J Cardiol199984663964310498131
   PubMed Web of Science ®Google Scholar